The role of systemic heparin administration at the time of open ruptured abdominal aortic aneurysm repair remains unknown. Our objectives were to compare postoperative outcomes in patients receiving nonfractionated heparin versus no heparin at the time of open ruptured abdominal aortic aneurysm (rAAA) repair in the Vascular Quality Initiative database. All patients who underwent open repair of rAAA between 2003 and 2020 in the Vascular Quality Initiative database were identified. 1:1 propensity score (PS) matching on 25 clinically relevant covariates was performed to match patients who received heparin to those who did not receive heparin. The primary outcome was all-cause mortality. The secondary outcomes were safety end points and included postoperative mortality, blood loss volume, number of packed red blood cell (pRBC) transfused, and complications (cardiac, renal, and respiratory). Survival was examined using Kaplan-Meier curves and compared using a Cox-proportional hazard model. Of 2410 patients that underwent open rAAA between 2003-2020, 1853 received heparin and 557 did not receive heparin. Before PS matching, patients that received heparin were younger (71.4 years vs 73.1 years), and less likely to present a American Society of Anesthesiologists class V at the time surgery (37.5% vs 48.7%). After PS matching, 519 pairs of patients had similar baseline characteristics and presentation (Table). Postoperative mortality was lower in the heparin group (37.6% vs 55.3%; P < .001). Estimated blood loss was 850 mL (95% confidence interval [CI], –350 to –1375 mL) lower in the heparin group and the median number of pRBC transfused was 2 units lower in the heparin group (interquartile range, –1 to –2.5; P < .001). There were no differences in postoperative renal dysfunction, respiratory failure, or congestive heart failure between the two groups. Overall, long-term survival was higher for patients who received heparin (hazard ratio, 0.62; 95% confidence interval, 0.53-0.72; P < .0001) at 10 years (Figure). Patients who received systemic heparin administration at the time of open rAAA repair showed significant survival benefit within 30 days and at 10 years. Heparin administration may have afforded a mortality benefit or been a surrogate for healthier and less moribund patient at the time of the procedure. Importantly, the administration of heparin did not result in increased bleeding or postoperative complications in this high-risk cohort.TableBaseline characteristics of patients before and after propensity score (PS) matchingAll patientsPS-matched patientsNo heparin (n = 557)Heparin (n = 1853)SMDNo heparin (n = 519)Heparin (n = 519)SMDDemographics Age, years, mean (SD)73.13 (8.73)71.47 (9.55)0.1872.99 (8.82)72.98 (9.10)<0.001 Female139 (25.0)421 (22.7)0.052131 (25.2)125 (24.1)0.027 Race0.0480.055Non-Whitea26 (7)103 (5.6)24 (4.6)19 (3.7)White509 (91.4)1668 (90.0)473 (91.1)475 (91.5)Unknown22 (3.9)82 (4.4)22 (4.2)25 (4.8) BMI, kg/m2, mean (SD)28.19 (5.80)28.14 (6.16)0.00928.22 (5.88)28.35 (6.30)0.021Comorbidities Hypertension421 (75.6)1426 (77.0)0.032391 (75.3)392 (75.5)0.004 Congestive heart failure44 (7.9)161 (8.7)0.02943 (8.3)41 (7.9)0.014 Chronic obstructive pulmonary disease162 (29.1)599 (32.3)0.07158 (30.4)156 (30.1)0.008 Preoperative creatinine, mg/dL, mean (SD)1.44 (0.83)1.38 (0.75)0.0691.44 (0.86)1.44 (0.74)0.01 Dialysis5 (0.9)12 (0.6)0.0295 (1.0)7 (1.3)0.036 Preoperative smoking status0.2690.055Never110 (19.7)297 (16.0)101 (19.5)105 (20.2)Prior175 (31.4)604 (32.6)166 (32.0)176 (33.9)Current238 (42.7)922 (49.8)228 (43.9)216 (41.6)Missing34 (6.1)30 (1.6)24 (4.6)22 (4.2) Prior coronary revascularization0.4410.088None283 (50.8)1207 (65.1)274 (52.8)265 (51.1)PCI or CABG81 (14.5)351 (18.9)79 (15.2)96 (18.5)Missing193 (34.6)295 (15.9)166 (32.0)158 (30.4) Prior aortic surgery40 (7.2)220 (11.9)0.1640 (7.7)39 (7.5)0.007Clinical presentation Hemoglobin, mg/dL, mean (SD)11.11 (2.29)11.68 (2.37)0.24511.15 (2.30)11.15 (2.28)0.004 Maximum AAA diameter, mm, mean (SD)79.82 (18.96)78.01 (31.77)0.06979.83 (19.12)81.55 (48.98)0.046 Concomitant iliac aneurysm115 (20.6)405 (21.9)0.03110 (21.2)121 (23.3)0.051 Mental status at presentation0.5240.032Normal298 (53.5)1425 (76.9)291 (56.1)292 (56.3)Disoriented108 (19.4)229 (12.4)102 (19.7)107 (20.6)Unconscious151 (27.1)199 (10.7)126 (24.3)120 (23.1) Systolic blood pressure <70 mm Hg278 (49.9)1361 (73.4)0.499274 (52.8)275 (53.0)0.004 Cardiac arrest150 (26.9)161 (8.7)0.491118 (22.7)110 (21.2)0.037 ASA class0.490.03811 (0.2)4 (0.2)1 (0.2)1 (0.2)22 (0.4)12 (0.6)2 (0.4)3 (0.6)320 (3.6)123 (6.6)19 (3.7)21 (4.0)4164 (29.4)886 (47.8)161 (31.0)159 (30.6)5271 (48.7)695 (37.5)251 (48.4)253 (48.7)Missing99 (17.8)133 (7.2)85 (16.4)82 (15.8) Time from symptom onset to incision, hours, mean (SD)16.65 (55.41)22.01 (47.19)0.10417.16 (57.28)16.45 (28.89)0.016Preoperative medications Aspirin203 (36.4)758 (40.9)0.092190 (36.6)199 (38.3)0.036 P2Y12 antagonist30 (5.4)176 (9.5)0.15730 (5.8)29 (5.6)0.008 Statin220 (39.5)780 (42.1)0.053205 (39.5)215 (41.4)0.039 Beta blocker229 (41.1)810 (43.7)0.053217 (41.8)212 (40.8)0.02 Anticoagulant or ACE-I/ARB0.480.03No216 (38.8)963 (52.0)211 (40.7)217 (41.8)Yes130 (23.3)574 (31.0)127 (24.5)128 (24.7)Missing211 (37.9)316 (17.1)181 (34.9)174 (33.5)Values are reported as number (%) unless otherwise indicated.AAA, Abdominal aortic aneurysm; ACE-I, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; ASA, American Society of Anesthesiologists; BMI, body mass index; CABG, coronary artery bypass graft; CHF, congestive heart failure; COPD, chronic obstructive pulmonary disease; PCI, percutaneous coronary intervention; P2Y12, purinergic receptor; SD, standard deviation; SMD, standardized mean difference.aNon-White race includes Asian, Black, American Indian, Alaskan Native, Native Hawaiian, or other Pacific Islander. Open table in a new tab
Read full abstract